Xenoport Inc. (XNPT) announced favorable preliminary results from a Phase 1 clinical trial after the close Thursday. The study was designed to assess the pharmacokinetics, safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate. The stock is now up 0.33 on 6K shares.
Xenoport declined during the first 2 hours of trade Thursday and finished down by 0.15 at $11.15. The stock closed near the middle of a 2 1/2 week range.
For comments and feedback: editorial@rttnews.com